An overview cost-utility analysis of prostate cancer screening.

I. M. Thompson, S. A. Optenberg

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


The value of prostate cancer screening remains controversial because of the high prevalence of the disease and the fact that many tumors detected through screening are not destined to lead to morbidity or mortality, rendering treatment unnecessary. An ongoing NCI-sponsored screening trial may eventually put an end to the controversy. However, in the meantime, cost-utility estimates suggest that the cost per crude and quality-adjusted life year gained from prostate cancer screening and treatment ranges from $8,400 to $23,100 (with an estimated 1 to 2.68 QALYs gained from screening and treatment), and that these estimates are actually lower than, or well within the range of, the costs of many commonly accepted medical interventions, including screening mammography in women under age 50 ($232,000) and treatment of hypertension with captopril ($82,600) or hydrochlorothiazide ($23,500). Thus, we conclude that prostate cancer screening may indeed be cost effective and should be offered to men in the at-risk age range.

Original languageEnglish (US)
Pages (from-to)141-145
Number of pages5
JournalOncology (Williston Park, N.Y.)
Issue number11 Suppl
StatePublished - Nov 1995

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'An overview cost-utility analysis of prostate cancer screening.'. Together they form a unique fingerprint.

Cite this